47% of the patients in this study had complete response (CR) on all oral regimen of decitabine–cedazuridine 5 days every 28 days plus venetoclax 400mg daily.
After 10 years one third of the heavily pretreated lymphoma patients who had CAR-T therapy stayed disease free.
An important post-hoc analysis from ARCHES and PROSPER that quantifies something we've suspected clinically, roughly 1 in 4 enzalutamide-treated patients who progress radiographically have no prostate-specific antigen (PSA) rise, and the majority won't meet PCWG2/3 PSA progression criteria. Liver metastases were 5-fold more common at radiographic progression on enzalutamide versus control, suggesting lineage plasticity and AR-independent clones are the culprit. Bottom line for practice: don't wait for PSA to rise before imaging your metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC) patients on ARPIs, periodic cross-sectional imaging, especially in the first two years, is warranted regardless of PSA trend.
Intriguing phase I signal for this next-generation paradox-breaker BRAF inhibitor with brain-penetrant properties. The 24% overall response rate (ORR) as a single agent is striking given that 60% of patients had prior BRAFi exposure, and seeing responses in that pretreated group is the most exciting finding. In BRAF-naïve colorectal cancer (CRC) specifically, a 24% ORR and 7.3-month progression-free survival (PFS) as monotherapy compares favorably to encorafenib/cetuximab in BEACON, which is a bold cross-trial comparison but hard to ignore. Safety looks cleaner than approved BRAFis, with no keratoacanthoma or palmar-plantar erythrodysesthesia, and a lower discontinuation rate. Brain penetrance showed early hints of intracranial benefit worth exploring further. One to watch closely as it moves into combinations.
Primary objective not met, ctDNA clearance post- neoadjuvant therapy (NAT) cannot reliably predict pathologic complete response (pCR) and shouldn't be used to defer surgery. But the prognostic data are striking: post-NAT ctDNA positivity independently predicted recurrence in triple-negative breast cancer (TNBC) (HR 8.9), and the postsurgical landmark analysis is essentially binary, 100% of ctDNA-positive patients recurred while 94% of ctDNA-negative patients were disease-free at 5 years (HR 128). Not practice-changing yet pending prospective utility trials, but this strongly validates ultrasensitive ctDNA as a prognostic tool and a smart enrollment biomarker for future escalation/de-escalation trials.
Encouraging phase I signal for this HER2-targeted Antibody-drug conjugate (ADC) in heavily pretreated GI cancers, 45% overall response rate (ORR) and 16.3mo median overall survival (OS) in HER2-positive gastric compares favorably with T-DXd benchmarks, and the 40.5% objective response rate (ORR) with 22.7mo OS in HER2-positive colorectal cancer (CRC) is notable. The 2% ILD rate looks meaningfully better than T-DXd’s reported range, which could be a real differentiator. Hematologic toxicity is substantial but manageable. Small China-only phase I, but worth watching closely as this advances.
Solid pragmatic phase II showing oxybutynin 2.5mg and 5mg BID (twice a day) both beat placebo for hot flash reduction in men on androgen-deprivation therapy (ADT), with no serious toxicities beyond expected dry mouth. Given that venlafaxine failed in this population and megestrol/medroxyprogesterone carry real concerns, this gives us an evidence-based option we can feel good about reaching for, especially in patients who also have urinary symptoms. Neurokinin B (NKB) antagonists are coming but not yet studied here, so oxybutynin fills a real gap now.
This large propensity-matched retrospective study of over 300,000 hospitalized patients should put to rest the long-standing reluctance to give IV iron during acute infection. Across MRSA bacteremia, pneumonia, UTI, colitis, and cellulitis, IV iron was associated with significantly better 14- and 90-day survival, improved hemoglobin recovery, and fewer transfusion days, with no increase in length of stay. The survival benefit was consistent and appeared early. Retrospective design with all the usual caveats, but the signal is clear and consistent across every infection type studied. If your patient has iron deficiency anemia and an acute infection, the data increasingly say treat it rather than wait.
Moving PARP inhibition earlier into the hormone-sensitive androgen pathway modulation–sensitive (APMS) setting, this trial shows talazoparib plus enzalutamide cuts the risk of progression or death in half (HR 0.48) in HRR-altered metastatic prostate cancer, with an impressive 3-year progression-free survival (PFS) of 77% versus 56%. The benefit extends beyond BRCA1/2 to ATM and CDK12 as well, which is clinically meaningful given that two-thirds of this population was non-BRCA.
Talquetamab plus daratumumab (with or without pomalidomide) delivered a striking progression-free survival (PFS) benefit over daratumumab plus pomalidomide and dexamethasone (DPd) in early-line relapsed/refractory myeloma, 24-month PFS of ~80% versus 51% and MRD-negative CR rates three times higher than the control arm. OS trending favorably but not yet mature. The GPRC5D toxicity profile is manageable but distinct, counsel patients upfront on taste changes, skin/nail effects, weight loss, and watch closely for ataxia/balance issues, which warrant holding the drug and early neurology involvement.